» Articles » PMID: 9651358

Structure-function Analysis of FLT3 Ligand-FLT3 Receptor Interactions Using a Rapid Functional Screen

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1998 Jul 4
PMID 9651358
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

FLT3 ligand (FLT3L) stimulates primitive hematopoietic cells by binding to and activating the FLT3 receptor (FLT3R). We carried out a structure-activity study of human FLT3L in order to define the residues involved in receptor binding. We developed a rapid method to screen randomly mutagenized FLT3L using a FLT3R-Fc fusion protein to probe the relative binding activities of mutated ligand. Approximately 60,000 potential mutants were screened, and the DNA from 59 clones was sequenced. Thirty-one single amino acid substitutions at 24 positions of FLT3L either enhanced or reduced activity in receptor binding and cell proliferation assays. Eleven representative proteins were purified and analyzed for receptor affinity, specific activity, and physical properties. Receptor affinity and bioactivity were highly correlated. FLT3L affinity for receptor improved when four individual mutations that enhance FLT3L receptor affinity were combined in a single molecule. A model of FLT3L three-dimensional structure was generated based on sequence alignment and x-ray structure of macrophage colony-stimulating factor. Most residues implicated in receptor binding are widely dispersed in the primary structure of FLT3L, yet they localize to a surface patch in the tertiary model. A mutation that maps to and is predicted to disrupt the proposed dimerization interface between FLT3L monomers exhibits a Stokes radius that is concentration-dependent, suggesting that this mutation disrupts the FLT3L dimer.

Citing Articles

A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule.

Hosseini I, Fleisher B, Getz J, Decalf J, Kwong M, Ovacik M Pharmaceutics. 2024; 16(5).

PMID: 38794321 PMC: 11125320. DOI: 10.3390/pharmaceutics16050660.


Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models.

Maiorova V, Mollaev M, Vikhreva P, Chudakov D, Kibardin A, Maschan M Int J Mol Sci. 2023; 24(8).

PMID: 37108788 PMC: 10146938. DOI: 10.3390/ijms24087626.


Evolution and Potential Subfunctionalization of Duplicated -Related Class III Receptor Tyrosine Kinase s and Their Ligands in the Allotetraploid .

Paiola M, Ma S, Robert J J Immunol. 2022; 209(5):960-969.

PMID: 36130129 PMC: 9512362. DOI: 10.4049/jimmunol.2200201.


Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines.

Maiorova V, Mollaev M, Vikhreva P, Kulakovskaya E, Pershin D, Chudakov D Vaccines (Basel). 2021; 9(11).

PMID: 34835169 PMC: 8621097. DOI: 10.3390/vaccines9111238.


Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death.

Molina M, Hoffman E, Stokes J, Kummet N, Smith K, Baker F Front Immunol. 2021; 12:699128.

PMID: 34249005 PMC: 8264365. DOI: 10.3389/fimmu.2021.699128.